title: [Multicentre clinical observation of anticoagulation and thrombolysis for the deep venous thrombosis].
abstract: OBJECTIVE
  Multicentre clinical observation for therapeutic efficacy and clinical safety of anticoagulation and thrombolysis in deep venous thrombosis (DVT).
  
  
  METHODS
  127 patients with DVT in left leg were randomly divided into four groups. Group A: treated with batroxobin. Group B: use Low Molecular Weight Heparin (LMWH). Group C: batroxobin and LMWH. Group D: urokinase and LMWH. Observing the perimeter of thigh and calf periodically, monitoring coagulation function, registering the frequency and degree of the complication.
  
  
  RESULTS
  All the treatments in four groups can relieve the swell level of the affected legs (P < 0.05). We got the best efficacy when we use batroxobin together with LMWH (P < 0.05), especially in treating the patients with a long course of treatment. Batroxobin can obviously reduce the level of blood FBG (P < 0.05), and have no significant effect with other index of coagulation function (P > 0.05). Inject ing batroxobin into affected legs with the micro pump got a better efficacy and much safer than intravenously guttae from peripheral vein.
  
  
  CONCLUSIONS
  Treating DVT with batroxobin got a definite efficacy, especially in cases with a long course of treatment; micro pumping can give a better effect and a high safety.
authors.affiliation: Harbin Medical University, Harbin 150086, China.
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Wang
authors.forename: Wei-liang
authors.initials: WL
authors.lastname: Jiang
authors.forename: Ying-nan
authors.initials: YN
authors.lastname: Zhang
authors.forename: Zhan-feng
authors.initials: ZF
authors.lastname: Sun
authors.forename: Qing-feng
authors.initials: QF
authors.lastname: Sun
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D012103:Batroxobin / Q000627:therapeutic use*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D012103:Batroxobin; D014568:Urokinase-Type Plasminogen Activator